THIS report describes the clinical, laboratory and genetic investigations of a large Negro family, many of whose members exhibit choreiform movements of early onset and nonprogressive nature. As far ...

Over 90 percent of people with Huntington’s disease develop chorea. Learn about FDA-approved VMAT2 inhibitors, off-label medications, and lifestyle strategies to manage involuntary movements.

An alternate, unitary explanation of these findings was suggested by a previous study from this hospital. 7 Data were presented showing that when chorea, rheumatic polyarthritis and carditis occur in ...

Medically reviewed by Huma Sheikh, MD Key Takeaways The medications approved by the Food and Drug Administration (FDA) for ...

Ingrezza (valbenazine) is a medication used to treat tardive dyskinesia (TD) and chorea associated with Huntington’s disease. These conditions cause involuntary movements like twitching, jerking, or ...

Chorea gravidarum is uncommon movement disorder of pregnancy, characterized by involuntary, abrupt, non-rhythmic movements. It can be idiopathic or secondary to the underlying pathology. A 28-year-old ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo. The drug valbenazine statistically improves chorea, a ...

People with uncontrolled movement problems can have a harder time doing everyday tasks such as speaking, reading, writing, and cooking, which can cause a loss of independence. This may cause people to ...

Please provide your email address to receive an email when new articles are posted on . Most patients with chorea and antiphospholipid antibody were women, with chorea onset at an average age of 22.8 ...

Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

Please provide your email address to receive an email when new articles are posted on . The new once-daily tablet strength doses are 30 mg, 36 mg, 42 mg and 48 mg. Symptom improvement in tardive ...

SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the ...